Kristen Andreatta

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Jean‐Michel Molina, Douglas Ward, Indira Brar et al. · The Lancet HIV · 2018 · 203 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

Eric S. Daar, Edwin DeJesus, Peter Ruane et al. · The Lancet HIV · 2018 · 180 citations

Medicine, Infectious Diseases, Pharmacology +16

Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness

Michael E. Abram, Rebecca Hluhanich, Derrick Goodman et al. · Antimicrobial Agents and Chemotherapy · 2013 · 111 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4

Nicolas Margot, Rebecca Hluhanich, G.S. Jones et al. · Antiviral Research · 2011 · 68 citations

Life Sciences, Infectious Diseases, Pharmacology +13

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

Kristen Andreatta, Madeleine Willkom, Ross Martin et al. · Journal of Antimicrobial Chemotherapy · 2019 · 62 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17